The ability of antiviral polyamides (AVP) to act upon polyomaviruses (PyV) was evaluated. Initial studies found that a single treatment of AVP protected SV40-infected BSC-1 cells from cytopathic effect (CPE) for as long as 11 days p.i.. AVP substantially suppressed SV40 genome copy numbers over the duration of the experiment. Immunofluorescence analysis of ataxia-telangiectasia mutated (ATM) activation and large T antigen (LTag) expression clearly demonstrated that AVP treatment at day 1 p.i. delayed the onset of productive SV40 replication by approximately 3 days, and substantially limited the infection relative to vehicle-treated controls. AVP dose-response experiments recorded IC50s in the low nM range that were similar to IC50s previously reported for HPV16. The ability of AVPs to act on BKPyV was next examined. Again, IC50s in the low nM range were obtained with the exception of an AVP (PA1) that gave an IC50 of 437 nM against the BKPyV Dunlop strain. The Mre11 inhibitor Mirin substantially reduced the AVP IC50 against SV40 demonstrating that Mre11 protects PyV genomes from AVP action as previously shown for HPV. Together these experiments show that AVPs are potent antiviral agents for PyV that act via a mechanism with similarities to that found for HPV. The results demonstrate that AVPs are useful tools for controlling and studying PyV biology. The potential use of these agents against BKPyV and other PyV pathogens also has clinical implications.
Introduction
Polyomaviruses (PyV) are a family of small (∼5000 bp) double stranded DNA (dsDNA) viruses that occupy a broad replicative niche in vertebrates from birds to humans, but individually have a narrow species tropism. PyV were once categorized with papillomaviruses (PV) in the family Papovaviridae due to their similarities as small, non-enveloped, icosahedral, covalently closed, superhelical, dsDNA tumor viruses. PyV and PV were separated into two families with the recognition that PyV possessed smaller capsids (45 nm vs. 55 nm), and smaller genomes (5 kB vs. 8 kB) with a genomic organization distinct from PV (Van Regenmortel et al., 2000) . Polyomaviridae is now composed of 3 genera: the bird PyV (Avipolyomaviruses) that have unique genetic and biological characteristics, and two mammalian genera, which comprise a unique set of human PyV (Wukipolyomaviruses) and the remaining mammalian PyV (Orthopolyomaviruses) based upon nucleotide divergence (Johne et al., 2011) . This latter group notably contains its type species, SV40, as well as BKPyV and JCPyV (Johne et al., 2011) , the first human PyV to be associated with disease that is particularly linked to immunosuppression (Dalianis and Hirsch, 2013) .
PyV and PV share notable similarities despite their taxonomic differences. For example, each family encodes one protein with enzymatic activity. PyV large T antigen (LTag) and PV E1 protein are both responsible for initiation of viral DNA replication and both have helicase domains dependent upon ATPase activity Bergvall et al., 2013) . Both PyV and PV also act to inhibit the key tumor suppressor pathways controlled by p53 and the retinoblastoma protein (pRB). In the case of PyV, LTag inactivates both p53 and pRB, while PV carries out these functions with two separate proteins: E6 blocks p53 and E7 inhibits pRb. Both virus families also activate and have complicated relationships with host cell DNA damage repair pathways (DDR). Many viruses, including PyV and human papillomaviruses (HPV), have been shown to use elements of DDR pathways to facilitate survival in the host cell (Luftig, 2014; McFadden and Luftig, 2013; Turnell and Grand, 2012) . PyV and HPV both recruit and use multiple homologous recombination repair elements to promote viral DNA replication (Chappell et al., 2016; Hong and Laimins, 2013; Sowd and Fanning, 2012; Sowd et al., 2013) . The ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) serine/threonine protein kinases sense DNA damage and organize repair processes, and both pathways are activated following PyV infection (Orba et al., 2010; Sowd et al., 2013;  https://doi.org/10.1016/j.antiviral.2018.02.012 Received 6 January 2018; Received in revised form 11 February 2018; Accepted 13 February 2018 Tsang et al., 2014; Zhao et al., 2008) . ATM primarily organizes the response to dsDNA breaks, while ATR has broader roles in responding to a variety of DNA damage including stalled replication forks and accumulation of single stranded DNA. The Chk2 and Chk1 kinases are activated downstream of ATM and ATR, respectively, where they act as important DDR organizers (Stracker et al., 2009 ). PyV LTag from many species are sufficient to disrupt genomic integrity and activate a DDR (Boichuk et al., 2010; Hein et al., 2009; Li et al., 2013; Orba et al., 2010) . The HPV E1 helicase alone is also sufficient to activate a broad DDR pointing to another notable similarity between the virus families (Fradet-Turcotte et al., 2011; Sakakibara et al., 2011) . Importantly, DNA replication, rather than LTag, is the principal activator of a DDR following infection of primary renal proximal epithelial (RPTE) by BKPyV (Verhalen et al., 2015) . These results point to the likely importance that unusual viral DNA replication-intermediate structures have in triggering recognition and activation of the DDR.
PyV have been associated with cancers in their hosts. JCPyV and BKPyV are linked with human disease, and additional PyV (such as KIPyV, WUPyV and MCPyV) have been isolated more recently from immune-compromised individuals (Ciotti et al., 2013; Dalianis and Hirsch, 2013) . PyV associated nephropathy (PyVAN), a major cause of renal allograft failure, is due to BKPyV in over 90% of cases. Since there are no approved antiviral treatments for PyVAN, the standard treatment strategy is reduction of immunosuppression, which often results in graft failure (Ambalathingal et al., 2017; Hirsch and Randhawa, 2013) . The need for antivirals to treat PyV's could not be clearer, but non-traditional approaches are needed since the small PyV genome grossly limits target selection.
Naturally-occurring, minor-groove DNA binding agents such as Distamycin A have long been of interest as antiviral agents but toxicity has limited their use (Becker and Weinber, 1972; Verini and Ghione, 1964) . Antiviral N-methylpyrrole-imidazole polyamides (AVPs) are higher order, synthetic homologs of Distamycin A that have remarkable activity against HPV episomes and display no cytotoxicity (Edwards et al., 2013a (Edwards et al., , 2011 (Edwards et al., , 2013b . AVPs were originally designed to bind in a sequence-specific manner to the HPV ori (Edwards et al., 2011) , but subsequent studies have shown that AVPs tolerate multiple base-pair mismatches and therefore bind more promiscuously to DNA (Koeller et al., 2014) . Size is an important property of AVPs that is required for activity: antiviral activity appears to require binding of at least ten bp or approximately one DNA helical turn (Edwards et al., 2011; Fisher, 2015; Koeller et al., 2014) .
AVPs bind to HPV episomes eliciting a cellular DDR that results in elimination of episomes. A number of DDR elements have been implicated in AVP action, but the MRE11-Rad50-Nbs1 (MRN) complex in particular appears to play an important role in protecting episomes from elimination (Edwards et al., 2013b; Fisher, 2015) . MRN recruits and activates ATM at DNA ends and thus plays a central role in dsDNA break repair (Harper and Elledge, 2007) . MRE11 and Nbs1 as well as CtIP, an endonuclease needed for efficient MRN-mediated homologous recombination that is essential for dsDNA break resection, are among the genes whose expression is significantly altered by AVPs (Edwards et al., 2013b; Sartori et al., 2007) . Importantly, the Mre11 exonuclease inhibitor Mirin (Dupre et al., 2008) acts as an AVP sensitizer in a manner that is analogous to DDR inhibitors that promote radiation and chemotherapy sensitization (Edwards et al., 2013b; Fisher, 2015; Kastan, 2008) . Mirin promotes damage by AVPs in HPV episomes in the form of dsDNA breaks resulting in reductions in AVP IC50s (Edwards et al., 2013b) . Thus Mre11 and the MRN complex appear to protect HPV extrachromosomal plasmids from damage and elimination by AVPs.
As discussed above, AVPs alter the highly evolved, advantageous relationship that HPVs maintain with the DDR machinery to one that promotes viral episome destruction. The similarities between PyV and HPV were therefore an important rationale for testing AVPs against PyV. We report here that AVPs have potent antiviral activity against SV40 and BKPyV. A single AVP treatment at day 1 p.i. protects cells from SV40 infection for as long as 12 days p.i.. Moreover, the Mre11 inhibitor Mirin acts as an antiviral sensitizer for PyV, as it does for HPV, resulting in a decrease in the AVP IC50. These results indicate that Mre11 plays an antagonistic role in antiviral polyamide activity against polyomaviruses as it does for HPV. The findings suggest that AVPs should be considered as possible candidates for treating PyV-related diseases. The ability to use SV40 and other PyV to study the unique antiviral mechanism of these compounds offers new experimental approaches not previously available.
Materials and methods

Cell culture
BSC-1 cells (ATCC-CCL-26) were maintained at a split ratio of 1:5 in Eagle's Minimal Essential Medium (MEM; Invitrogen)-10% Fetal Bovine Serum (FBS; Invitrogen) plus 50U/mL penicillin-streptomycin (Life Technologies, cat # 15070063). Primary human renal proximal tubule epithelial cells (RPTE cells; ATCC-PCS-400-010) were maintained for up to 10 cell passages (plating density of 5000 viable cells per cm 2 ) in renal epithelial cell growth medium (REGM; ATCC-PCS-400-030) supplemented with recombinant human epidermal growth factor (10 ng/ mL), triiodothyronine (10 nM), hydrocortisone (100 ng/mL), recombinant insulin (5 μg/mL), epinephrine (1 μM), transferrin (5 μg/ mL), 0.5% fetal bovine serum (Renal Epithelial Cell Growth Kit; ATCC-PCS-400-040) and GA-1000 (30μg/mL gentamicin and 15 ng/mL amphotericin B; Lonza cat # CC4083). For long-term BKPyV infections, such as propagation to produce high-titer stocks, RPTE cells were cultured with 5% FBS.
Viruses
SV40 (ATCC, VR-820) strain PML-1 (EK) was propagated by infection of 80-100% confluent BSC-1 cells in T75 culture flasks (Corning) at a multiplicity of infection (MOI) of 0.01 in 2 mL MEM + 2% FBS. Virus was adsorbed for 2 h with rocking every 15 min, MEM-2% FBS was added up to 10 mL, and cells incubated at 37°C in a humidified incubator in 5% CO 2 . After 4 days, media was replaced with fresh MEM-2% FBS and incubation was continued until signs of cytopathic effects (CPE) were observed. When CPE completely destroyed the monolayer, the flasks were removed from the incubator and placed at −20°C overnight, thawed at RT, and the freeze/thaw cycle repeated 3 times. The viral stock was then cleared of cellular debris by centrifugation at 200×g for 5 min at RT. Virus stocks were aliquoted and stored frozen at −80°C. For determination of titer, serial dilutions of SV40 stocks were prepared in MEM-2% FBS from 10 −2 to 10 −10 and 1 mL added to newly confluent p60 dishes of BSC-1 cells for 2 h at 37°C with rocking every 15 m. Media was removed and cultures were overlaid with 4 mL of a mixture containing 1.8% Bacto™ Agar (BD Biosciences, cat # 214010) cooled to 45°C and 2X MEM (Temin's modification no phenol red; Life Technologies, cat # 11935-046) plus 10% FBS. Mixture was allowed to solidify at RT for 15 m and then plates were placed in a humidified CO 2 incubator at 37°C. After 3 days, cells were fed by overlaying an additional 3 mL of agar mixture and then on day six, neutral red (Sigma, cat. # N4638) was added to the overlay mixture at a final concentration of 100 μg/mL. Plaques were counted and titer determined on day 9. TU and Dunlop (Dun) strains of BKPyV (provided by M. Imperiale, University of Michigan) were used to infect renal proximal tubule epithelial (RPTE cells). High-titer stocks were prepared following conventional protocols (Abend et al., 2007) . RPTE cells were infected when 70-80% confluent with 3 ml seed virus (diluted in REGM/5% FBS) per 75 cm 2 cell growth area at an MOI of 0.5 (fluorescence forming units)/ cell and virus allowed to adsorb for 1 h at 37°C in a humidified incubator with 5% CO 2 . There are approximately 1000 viral genomes per infectious unit. Following incubation, an additional 7 ml of fresh REGM/5% FBS was added without aspiration of virus inoculum. Infections were allowed to proceed until advanced signs of CPE were evident (3-4 weeks) with media changes once per week. Viral lysates were prepared by freeze (−80°C)/thawing°C) cells 3X and scraping still attached cells into the media. The cells were disrupted by sonication in a water bath until the suspensions appeared homogenous (1-3 m). The cultures were then clarified by centrifugation at 1500×g (15′ at 4°C) to remove cellular debris. Virus stocks were aliquoted and stored frozen at −80°C. BKPyV stocks were titered using fluorescent antibody (FA) focus-forming assays following standard protocols (Abend et al., 2007) . Passage 6 or lower RPTE cells were cultured on cover glass in 24-well plates in REGM with 0.5% FBS. When cells were 70% confluent, triplicate wells were infected with 10-fold serial dilutions of BKPyV stock in REGM/0.5% FBS, 200 μL added per well and cells incubated 72 h at 37°C in a humidified incubator with 5% CO 2 . Infections were then supplemented with an additional 300 μl REGM/ 0.5% FBS to each well and incubated 48 h. Cells were fixed with 50% methanol-50% acetone at room temperature for 10′, air-dried for 15′ and stored overnight at −20°C. distilled water wash, cover slips were mounted onto slides with media containing DAPI (Molecular Probes, cat # P36931) and analyzed by fluorescence microscopy. To determine BKPyV titer, fluorescent foci were counted in five random fields of infected cells on each cover slip and the average calculated for each virus dilution. The average number of infected foci counted was then multiplied by the reciprocal of the volume of virus added to each well multiplied by the reciprocal of the dilution factor. Titer is expressed as infectious units per ml (IU/ml) or fluorescence-forming units per mL (FFU/ml).
Antiviral polyamides (AVPs)
The synthesis and preparation of the AVPs (PA1 = 98% purity; PA25 = 95% purity) used in this study were previously described (Edwards et al., 2011 (Edwards et al., , 2013b .
qPCR
qPCR reaction mixtures contained 8 μL sample DNA, 200 nM each primer, 250 nM probe and 10 μL 2X Master Mix (LightCycler 480 Probes Master; Roche, cat # 04887301001) in a total volume of 20 μL. Samples were analyzed using a LightCycler 480 (Roche). Drug effects on viral DNA copy number were calculated as a percentage of viral DNA copies quantified in DMSO-treated cells relative to known copy number of cloned DNA in a standard curve, the log-dose response plotted, and IC50s calculated using best-curve fitting software (XLfit; IDBS, United Kingdom) as previously reported (Edwards et al., 2011) .
Primers and probe for SV40: forward 5′-CCTCCGTTAAGGTTCGTA GGTCA-3′ reverse 5′-CAGCGCTCACACCAGTC-3′ probe 5'-/56-FAM/ATTGAAGTGCAACTTGCATCTGTTGCTACTGTT GA/3BHQ_1/-3'.
Cycling conditions: 10 min at 95°C followed by 40 cycles of 95°C for 30 s and 60°C for 60 s.
Primers and probe for BKPYV: forward 5′-CCCAGGAGGTGCAATC AAAGA-3′ reverse 5′-TCATATGCTTCAAGAGCAGGTGT-3′ probe 5'-/56-FAM/TTCTAGGCCTGTACGGGACTG/3BHQ_1/-3'. Cycling conditions: 10 min at 95°C followed by 40 cycles of 95°C for 15 s and 60°C for 30 s.
SV40 qPCR assays
BSC-1 cells were plated at 5 × 10 5 cells per well in 24-well plates.
Upon reaching 90-100% confluence, SV40 virus was added in 50 μL MEM-2% FBS in each well at a MOI equal to 1. Virus was allowed to adhere to cells for 2 h at 37°C in a humidified incubator with 5% CO 2 at which time virus was removed and 0.5 mL MEM-2% FBS was added to each well. Infection was allowed to proceed for 24 h before increasing doses of PA from 0.001-10μM or 0.1% DMSO was added to culture wells and incubated an additional 48 h. Following the treatment period, DNA was extracted with DNAzol (Life Technologies, cat # 10503-027) according to the manufacturer's recommendation for qPCR (below).
SV40 plaque assay
BSC-1 cells were plated at 2 × 10 6 cells per 60 mm dish and the following day infected with SV40 at an MOI = 0.1. Virus was adsorbed for 2 h at 37°C in a humidified incubator with 5% CO 2 with rocking every 15 m at which time virus was removed and MEM-10% FBS containing 0.1% DMSO or 10 μM PA25 was added to each well. The media was changed every three days and cells harvested by scraping for titer assay on day 11 p.i. Cells were freeze/thawed 3 times and titered on BSC-1 cells (6-well plates at 1 × 10 6 cells/well) from 10 −1 to 10
dilutions. Following 2 h adsorption, virus was removed and cells overlayed with bacto-agar/MEM/5% FBS. After 3 days, cells were fed by overlaying additional agar media. Neutral red was added on day six p.i., and plaques were counted on day 10.
BKPyV assay
RPTE cells were plated at 1 × 10 5 cells per well in 24-well plates and infected, when confluent, with 50 μl BKPyV-TU or BKPyV-Dun per well at an MOI of 0.5 FFU/cell diluted in REGM with 0.5% FBS. Virus inoculum was removed after 2 h and replaced with 500 μL fresh REGM-0.5% FBS. BKPyV infected RPTE cells were cultured for 48 h and then increasing doses of PA from 0.001-10μM, or 0.1% DMSO (vehicle control), was added to culture wells and incubated an additional 48 h, at which time DNA was extracted with DNAzol for qPCR (below).
MTT viability assay
Cell viability was measured using a cell viability assay kit (ATCC, cat# 30-1010 K) as previously reported (Edwards et al., 2011) . Briefly, 10 μL tetrazolium MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to wells containing uninfected BSC-1 or RPTE cells that had received AVP or vehicle (0.1% DMSO). Intracellular purple formazan precipitate was solubilized in detergent according to kit directions, the absorbance was read at 595 nm, and the data was plotted as the percentage of viable cells following 48 h of drug treatment compared with vehicle-treated cells.
Mre11 inhibitor studies
BSC-1 cells were plated and infected as above with SV40. 24 h later increasing doses of PA25 from 0.001-10μM ± 100 μM Mirin (Sigma, cat # M9948) or 0.1% DMSO was added for an additional 48 h. At the end of the treatment period, total DNA was harvested with DNAzol and 20 ng total DNA analyzed by qPCR.
Immunofluorescence
BSC-1 cells were seeded onto coverslips at 1 × 10 5 cells per well of 12-well plates and cultured until 90-100% confluent. Cells were infected with SV40 virus (MOI = 1) in MEM + 2% FBS for 2 h at 37°C at which time virus-containing media was removed and cells incubated with fresh media for 24 h. Virus-infected cells were then treated with 0.1% DMSO or 10 μM PA25 and cultured for an additional 10 days with coverslips harvested each day for assessment of the relationship between timing of LTag expression, phosphorylation of ATM, and virusinduced cell lysis. Coverslips were also harvested for Giemsa staining (see methods below) and DNA was extracted from remaining cells for quantitative analysis of SV40. Coverslips were fixed in 3.7% paraformaldehyde for 5 min at RT and washed three times with PBS. Cells were then permeabilized in 0.2% Triton X-100 in PBS for 5 min at RT and washed 3X with PBS. Nonspecific antigen binding was blocked by incubation of cells with 3% Bovine serum albumin (BSA) in PBS for 30 min at RT. Primary antibody dilutions were prepared in 1% BSA in PBS. LTag was recognized with antibody PAb416 (Abcam, cat # ab16879) at 1:200 dilution and Phospho S1981 ATM (pATM) with EP1890Y (Abcam, cat # ab81292) at 1:250 dilution with r.t. incubation for 2 h. Coverslips were washed 3 × 10 min each with PBS. Secondary antibodies were diluted in 1% BSA-PBS at 1:500 dilution; LTag was detected with goat anti-mouse AlexaFluor 546 (Life Technologies, cat # A11056) and pATM with goat anti-rabbit AlexaFluor 488 (Life Technologies, cat # A11055). Coverslips were incubated with secondary antibodies for 2 h at r.t. and then washed 3 × 10 m. each with PBS. Nuclei were visualized by including DAPI in the mounting solution (ProLong Gold with DAPI; Life Technologies, cat # P36931).
Giemsa staining
BSC-1 cells were seeded onto coverslips and treated identically as immunofluorescence methods above. On each day, media was aspirated and coverslips washed 1X with PBS followed by incubation with anhydrous methanol for 2 min at r.t. Methanol was removed and cells were stained with neat, 0.2 μm filtered Giemsa stain (Sigma, cat # 48900) for 5 min at RT. Giemsa stain in each well was then diluted 4X with PBS and allowed to incubate an additional 5 min, followed by extensive rinsing under tap water until clear. Coverslips were then rinsed with deionized water and allowed to air dry overnight at r.t. in the dark. Coverslips were then mounted with Histomount (Life Technologies, cat # 008030).
Results
PA25 effects on productive SV40 infection of BSC-1 cells were initially assessed by light microscopy. BSC-1 cells were infected with SV40, the infection allowed to proceed for 24 h, and then treated with 10 μM PA25. Uninfected BSC-1 cells maintained a confluent monolayer over the entire culture period, while the SV40 infected cultures began showing evidence of monolayer disruption, and cell vacuolization and loss by day 6 p.i. (Fig. 1) . Cell loss was complete by day 8 p.i.. Infected cultures receiving PA25, on the other hand, retained adherent cells for the entire culture period (Fig. 1) . Some cell monolayer disruption became evident by day 9 p.i., but greater than 50% confluence was maintained until the experiment was stopped at day 11 days p.i..
The effects of PA25 treatment on SV40 DNA levels following infection were next examined by qPCR (Fig. 2) . Cells were infected with SV40 at a multiplicity of infection (MOI) equal to 1, as above. Total cells (adherent + non-adherent cells) were collected on each day for preparation of DNA so that viral DNA could also be sampled in nonadherent cells after day 6 p.i.. Infected BSC-1 cells (MOI = 1) exhibited a large increase in total SV40 viral DNA copies between 3 and 4 days p.i., and those levels continued to rise until the experiment was ended at day 11 p.i. (Fig. 2) . A single treatment of BSC-1 cells with 10 μM PA25 at day 1 p.i., on the other hand, had an inhibitory effect on SV40 DNA levels. A relatively small increase in viral DNA levels was noted in treated cells between 4 and 7 days p.i., followed by an increase between 7 and 9 days p.i. that plateaued at approximately 20% of the viral DNA levels attained in untreated cultures (Fig. 2) .
Experiments were designed to follow the expression of SV40 large T antigen (LTag) and pATM in order to better understand how the kinetics of viral DNA infection may be altered by antiviral polyamides (Fig. 3) . Infected BSC-1 cells showed evidence of viral infection at day 1 p.i., with expression of pATM and LTag in a small subset of cells. The levels of pATM and LTag expression steadily increased between days 2 and 6 with peak expression occurring on day 6, after which cell loss considerably reduced the numbers of labeled cells. Detection of pATM expression preceded LTag detection: the faintest cells expressing pATM often did not co-express detectable LTAg at the earliest time points, although the coincidence of expression in the brightest cells was robust, cumulating at day 6 p.i.. Adherent cells were rapidly lost after day 6 p.i.. Fluorescence was also quantified by counting positive nuclei so the wave of SV40 expression could be tracked over time by following DAPI, pATM, and LTag positive nuclei (Fig. 4) . A single 10 μM PA25 treatment significantly delayed pATM and LTAg expression (Figs. 3 and 4) . Faint pATM fluorescence was noted at day 2 p.i. (day 1 post-PA25 treatment) that was equivalent to low level pATM expression seen immediately following infection in untreated day 1 p.i. cells (Fig. 3) . However the appearance of bright pATM and LTag positive cells was significantly delayed throughout the entire culture period (Figs. 3 and 4 ) and did not reach its peak until day 11 p.i.. It was apparent, by comparing the wave of expression in control versus treated cells, that expression of pATM and LTag was delayed by 3 days since peak expression in untreated cells occurred at 6 days and in PA25-treated cells occurred at days 9 and 10 p.i. (Fig. 4) . Cell loss began gradually in the PA25-treated cell population with a trend beginning at day 6 p.i. and eventually culminating in approximately 50% loss by day 11 p.i.. Therefore, a single PA25 treatment delivered at day 1 p.i. attenuated the extent and magnitude of SV40 infection, resulting in protection of approximately 50% of cells 10 days after treatment. Measurement of SV40 PFUs at 11 days p.i. found 2.17 × 10 8 pfu/mL for cells receiving 0.1% DMSO and 1.20 × 10 7 pfu/mL for cells receiving AVP. Thus a single AVP treatment at day 1 p.i. resulted in a 18-fold reduction of infectious virus progeny. Both PA25 and PA1 were previously shown to destabilize HPV viral episomes, resulting in their rapid loss from episome maintaining cell lines (Edwards et al., 2011 (Edwards et al., , 2013b . We therefore tested the ability of PA25 and PA1 to cause loss of viral DNA from BSC-1 cells that had been infected for 24 h with an SV40 MOI of 1 (Fig. 5) . Dose responses for both PA25 and PA1 were conducted and IC50's derived from the curves calculated from data combined from 3 independent experiments (Fig. 5) . Both PA25 and PA1 drove SV40 copy numbers to nearly undetectable levels (10μM dose routinely results in Ct values of 35-40 with 20 ng input DNA) after 48 h of treatment, at which point PA25 gave an IC50 of 32 nM and PA1 produced an IC50 of 218 nM. As measured by MTT assay, total DNA isolation, and microscopic examination, no adverse effects on BSC-1 cell fitness or viability were noted for either compound during the course of the experiment (Fig. 5) . The lack of toxicity and failure to calculate a TD50 in these experiments does not permit calculation of a selectivity index as previously reported for AVPs in HPV episome-containing cells (Edwards et al., 2011) .
In order to determine if other polyomaviruses may be susceptible to AVP antiviral activity, we next examined compound effects on BKPyV. Confluent RPTE cells, infected with either BKPyV-Tu or BKPyV-Dun for 48 h, were tested with increasing concentrations of AVP (PA25 and PA1) between 1 nM and 10 μM. As for SV40, both compounds exhibited high potency against the two BKPyV strains. Both compounds reduced viral copy numbers to very low levels at the highest doses while recording IC50's of 7 nM and 437 nM against BKPyV-Dun, and 1 nM and 62 nM against BKPyV-Tu, for PA25 and PA1, respectively (Table 1) . No deleterious effects for AVP on RPTE cell fitness or viability were noted. The PA1 and PA25 IC50s for both SV40 and BKPyV were similar to previously reported HPV IC50s suggesting that the compounds may be working against the two virus families by a similar mechanism (Table 1) . Previous mechanistic studies of antiviral polyamide activity identified a role for the MRN complex in controlling episome elimination (Edwards et al., 2013b) . In particular, MRE11 acted as a repressor of AVP antiviral activity, and the MRE11 exonuclease inhibitor Mirin sensitized HPV episomes to AVP antiviral activity (Edwards et al., 2013b; Fisher, 2015) . It was therefore of interest to examine the effects of Mirin on AVP activity against polyomaviruses. BSC-1 cells were infected with SV40 (MOI = 1) and increasing doses of PA25 from 1 nM to 10 μM were provided 24 h later in the presence of 100 μM Mirin or 0.1% DMSO. A shift in dose response curves (summarizing 3 independent experiments) demonstrated that Mirin sensitizes SV40 DNA to elimination by antiviral polyamides (Fig. 7) . Control cultures, which received vehicle (0.1% DMSO), gave an IC50 of 32 nM. The addition of Mirin resulted in a leftward IC50 curve shift that reduced the IC50 from 32 nM to 12 nM (Fig. 7) . Addition of Mirin alone had no effect on SV40 copy number (data not shown).
Discussion
Here we show that a single AVP treatment protected BSC1 cells from SV40 CPE. This antiviral result coincided with substantial repression of viral genome replication as measured by both Q-PCR and viral LTag expression. BSC-1 cell lysis due to infection was completed by 8 days p.i., while AVP treatment at day 1 p.i. resulted in substantial cell survival even at 11 days p.i.. AVP treatment significantly attenuated viral replication up to 7-8 days p.i. at which point SV40 copy number began to modestly increase. The wave of SV40 infection spreading through the BSC-1 cell monolayer was measured by following expression of LTag and the appearance of activated ATM, a marker of SV40 infection (Zhao et al., 2008) . AVP treatment delayed the wave of SV40 infection by ∼3 days, and significantly attenuated the infection peak at 9 days p.i.. These results suggest that AVP-mediated BSC-1 cell protection from SV40 CPE at 11 days p.i. is attributable to both a delay and attenuation of the infectious wave.
Antiviral polyamides that cause the extensive loss of HPV episomes from cells recognize at least 10bp of linear DNA sequence (Edwards et al., 2013a (Edwards et al., , 2011 (Edwards et al., , 2013b . Multiple lines of evidence point to DNA damage repair (DDR) pathways as important for the HPV antiviral activity. DDR pathways are broadly altered following antiviral polyamide treatment in HPV episome-maintaining cells, but not in HPV-negative C33A cells or SiHa cells that carry only integrated HPV sequences (Edwards et al., 2013b) . These observations suggest that the circular ∼7.9 kb HPV genome, which is otherwise protected from cell surveillance mechanisms, is altered by AVP binding and subsequently eliminated (Edwards et al., 2013b; Fisher, 2015) . Numerous DDR elements, including homologous recombination pathway members, are associated with HPV replication centers (Chappell et al., 2016; Gillespie et al., 2012; Sakakibara et al., 2011) . The close association may allow for rapid recognition and elimination of viral DNA following AVP binding. Polyomaviruses also recruit homologous recombination elements to replication centers (Boichuk et al., 2010; Rohaly et al., 2010; Zhao et al., 2008) where they contribute to viral DNA replication (Dahl et al., 2005; Shi et al., 2005) . It is therefore reasonable to hypothesize that a Fig. 3 was morphometrically analyzed using Nikon NIS-Elements software in order to quantify the wave of SV40 infection detected by appearance of pATM and LTag. DAPI stained nuclei are representative of total cell numbers. Total numbers of DAPI-, pATM-, and LTag-labeled nuclei from five fields were counted. similar or related mechanism of action may be at play against PyV.
The elimination of SV40 and BKV genomes following treatment with high levels of AVP (Figs. 5 and 6) suggests that PyV episomes may be destabilized and lost in a manner similar to HPV. Both SV40 and BKPyV are potently suppressed by AVPs with IC50s that are similar to those previously reported for HPV in spite of remarkably different assay conditions. The PyV assays are dependent upon infection of cell monolayers, while HPV assays are conducted with cells that stably maintain episome levels over long-term culture. However, the relative potency of the AVPs is preserved against both SV40 and BKPyV. As with HPV, PA1 is less potent than PA25 for both SV40 and BKPyV. AVP activity against BKPyV results in IC50's that are in the low nM range. One exception is the BKPyV-Dun strain, which requires 437 nM for a 50% reduction in copy number relative to controls ( Fig. 6; Table 1 ). These data are consistent with a similar AVP mechanism of action for both PyV and HPV. It is highly likely that other PyV will also be susceptible to the broad antiviral activity of these compounds.
Additional evidence for a similar AVP mechanism against the two virus families is provided by experiments showing that Mre11 inhibition reduces the AVP IC50 against PyV. Three independent experiments conducted with SV40 demonstrated decreases in IC50 from 32 nM to 12 nM. In the case of HPV, several lines of evidence point to the involvement of the MRN complex in AVP-mediated destruction and loss of episomes (Edwards et al., 2013b; Fisher, 2015) . MRN genes MRE11 and NBS1 are transcriptionally regulated in response to AVPs, and MRE11 is a genetic repressor of AVP activity. The MRN complex is 36 ( ± 0.4) 32 ( ± 0.3) 1 ( ± 0.0001) 7 ( ± 0.001) Fig. 6 . Dose response assays were conducted by following BKPyV (genotype Dun) copy number after infection of RPTE cells and 48 h exposure to PA1 and PA25 in order to assess AVP potency. MTT assays for RPTE cell viability were conducted in parallel. Both AVPs exhibited potent antiviral activity against BKPyV in the absence of measurable cytotoxicity. recruited to both SV40 and HPV replication centers where it interacts with SV40 LTAg and HPV E7 (Anacker et al., 2014; Digweed et al., 2002; Lanson et al., 2000; Wu et al., 2004) . The data reported here is consistent with Mre11 protecting PyV episomes from AVP activity. It was previously shown that AVPs produce dsDNA breaks in HPV episomes and that Mirin dramatically enhances this effect (Edwards et al., 2013b) . We therefore hypothesize that Mre11 and MRN act in an antagonistic manner against AVPs to protect PyV genomes, perhaps by promoting dsDNA break repair. PyV's have numerous advantages as models for studying antiviral mechanisms. The present findings significantly enhance the ability to design future experiments seeking to understand the pathways controlling viral DNA persistence and elimination. Specific antiviral treatments for PyV are needed. We report here that AVPs potently reduce PyV genomes and limit the infectious spread of virus as observed by a delayed onset of CPE. Substantial reductions in viral DNA load are noted following a single AVP treatment in vitro indicating that an optimized treatment schedule has potential for significant improvement of efficacy. We also provide the first data showing that the AVP mechanism of action against PyV has parallels to previous reports for HPV. In addition to the potential clinical implications of these observations, our findings also provide a framework for guiding new antiviral studies of PyV. The nature of PyV relationship with the cellular DDR machinery, and in what way the relationship contributes to the host cell ability to recognize and eliminate viral genomes, are both topics of basic and practical importance for future studies.
